The aim of this study was to assess the value of NT-proBNP in addition to the LV-GLS in detecting early sub clinical ventricular dysfunction (as early as 6 weeks of the first chemotherapy dose) in breast cancer female patients. The gene discussed is NPPB; the disease is breast cancer.